POCARED Diagnostics announces closure of another $15M in funding

POCARED Diagnostics Ltd. is an Israeli-based Diagnostics and Pre-analytical technology manufacturer with offices in the United States announced they have closed another $15 Million in funding.

POCARED Diagnostics Ltd. is the developer of leading technology platforms that dramatically improve the ability of practitioners and hospitals to implement evidence-based medicine, while reducing lab operating costs and improving profitability. The company raised an additional $15 million (milestone-based) in funding to complete its clinical trials and increase manufacturing capacity while preparing to commercialize both the POCARED P-1000^TM and SP platforms.

The POCARED P-1000^TM analysis platform offers direct- specimen, fully automated, reagent-free microorganism detection, Identification and enumeration, in minutes, by utilizing intrinsic fluorescence optical data .The SP is the next-generation sample processor delivering second-to-none cell recovery, viability and robust fractionation capabilities. These technologies will be as an aid in the diagnosis of infectious diseases.

"These are exciting times for POCARED™ as we are closer to commercializing our first two platforms to make the POCARED™ revolution a reality" says Jonathan Gurfinkel, the company President and CEO. Mr. Gurfinkel goes on to say "The funding allows us to quickly build capacity in manufacturing and to begin development of further applications for the system."